NASDAQ:ARNA Arena Pharmaceuticals (ARNA) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free ARNA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$99.99▼$99.9950-Day Range$93.13▼$99.9952-Week Range$45.50▼$100.00Volume107 shsAverage Volume1.56 million shsMarket Capitalization$6.17 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Arena Pharmaceuticals alerts: Email Address Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Arena Pharmaceuticals Stock (NASDAQ:ARNA)Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.Read More Ad Monument Traders AllianceMake This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…See Why This $3.00 Stock Could Hit $15.00 ARNA Stock News HeadlinesAugust 31, 2023 | uk.investing.comArwana Citramulia Tbk (ARNA)August 21, 2023 | foxnews.comMLS club places Bruce Arena on leave over probe into 'allegations of insensitive and inappropriate remarks'March 18, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…May 23, 2023 | bizjournals.comRNA startup launches with $300M, Merck partnershipMay 23, 2023 | seekingalpha.comLongboard Pharmaceuticals: Undervalued Arena Spin-Out Has 2 Data Catalysts Due In 2023May 6, 2023 | cnbc.comPfizer earnings and revenue top expectations despite Covid vaccine sales declineApril 25, 2023 | health.usnews.comArna L. DavidsonApril 12, 2023 | foxnews.comPortland, Maine, reopens basketball arena to migrantsMarch 18, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. March 17, 2023 | forbes.comIs Pfizer Stock Undervalued At $40?February 9, 2023 | benzinga.comArna Marketing Group Continues Investing in State-of-the-art Canon Inkjet Technology to Deliver "The Arna Advantage"February 8, 2023 | finance.yahoo.comArna Marketing Group Continues Investing in State-of-the-art Canon Inkjet Technology to Deliver “The Arna Advantage”February 6, 2023 | msn.comA DNA protein may be responsible for causing cancerous ‘stress balls’ in the body: U of S researchAugust 23, 2022 | thestreet.comObesity Drugs: The Road to PerditionAugust 9, 2022 | baystreet.caPfizer to Buy Global Blood TherapeuticsAugust 4, 2022 | forbes.comShould You Buy Pfizer Stock After An Upbeat Q2?June 29, 2022 | forbes.comShould You Buy, Sell, Or Hold Pfizer Stock At $52?May 3, 2022 | theglobeandmail.com7 Biotech Stocks With Key Catalysts in MarchMarch 10, 2022 | seekingalpha.comPfizer confirms HSR waiting period for Arena Pharmaceuticals deal expiredMarch 7, 2022 | seekingalpha.comArena Pharma gains after report Pfizer deal will clear without HSR second requestFebruary 25, 2022 | seekingalpha.comArena Pharmaceuticals GAAP EPS of -$2.54 misses by $0.31February 24, 2022 | msn.comArena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in FocusFebruary 23, 2022 | uk.finance.yahoo.comSFO opens criminal probe into collapse of Arena TelevisionFebruary 23, 2022 | finance.yahoo.comArena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program UpdatesFebruary 9, 2022 | finance.yahoo.comArena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23February 9, 2022 | benzinga.comHC Wainwright & Co. Downgrades Arena Pharmaceuticals to Neutral, Lowers Price Target to $100February 9, 2022 | markets.businessinsider.comExpert Ratings For Arena PharmaceuticalsSee More Headlines Receive ARNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ARNA CUSIP04004710 CIK1080709 Webwww.arenapharm.com Phone(858) 453-7200Fax858-453-7210Employees448Year Founded1977Profitability EPS (Most Recent Fiscal Year)($10.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-616,430,000.00 Net MarginsN/A Pretax Margin-1,141,542.63% Return on Equity-69.83% Return on Assets-62.35% Debt Debt-to-Equity Ratio0.05 Current Ratio8.59 Quick Ratio8.59 Sales & Book Value Annual Sales$50,000.00 Price / Sales123,305.67 Cash FlowN/A Price / Cash FlowN/A Book Value$10.94 per share Price / Book9.14Miscellaneous Outstanding Shares61,659,000Free Float60,173,000Market Cap$6.17 billion OptionableOptionable Beta0.55 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Amit D. Munshi M.B.A. (Age 54)Pres & CEO Comp: $1.22MMs. Laurie D. Stelzer (Age 54)Exec. VP & CFO Comp: $630.76kMr. Vincent E. Aurentz (Age 54)Exec. VP & Chief Bus. Officer Comp: $692.82kDr. Christopher H. Cabell FACCM.D., MHS, AdvisorMr. Robert Lisicki (Age 54)Exec. VP & Chief Commercial Officer Comp: $686.63kDr. Douglas A. Bakan Ph.D.Exec. VP of Technical OperationsDr. Lamine Mbow Ph.D.Sr. VP & Chief Scientific OfficerMegan E. KnightDirector of Investor RelationsPatrick MalloyVP of Investor Relations & Corp. CommunicationsMr. Michael E. Paolucci (Age 62)Exec. VP of HR More ExecutivesKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSChemoCentryxNASDAQ:CCXIAmicus TherapeuticsNASDAQ:FOLDView All Competitors ARNA Stock Analysis - Frequently Asked Questions How were Arena Pharmaceuticals' earnings last quarter? Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.53) by $0.68. During the same quarter last year, the business earned ($1.69) earnings per share. When did Arena Pharmaceuticals' stock split? Arena Pharmaceuticals shares reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO? 16 employees have rated Arena Pharmaceuticals Chief Executive Officer Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among the company's employees. What other stocks do shareholders of Arena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T). This page (NASDAQ:ARNA) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetryDid you make $29,000 two days with AI options trades?Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.